Author

Mohammad W. Bahar

University of OxfordORCID 0000-0002-2350-2682Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:protein structure· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Approach:statistical model· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

David Ian StuartiD· 3 shared Elizabeth E. FryiD· 3 shared Andrew J. MacadamiD· 2 shared Claudine PortaiD· 2 shared David J. RowlandsiD· 2 shared Helen FoxiD· 2 shared Jessica J. Swanson· 2 shared Keith GrehaniD· 2 shared

Activity by Year

2022-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

David Ian StuartORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Microbiologynpj VaccinesPeer-reviewedMar 31, 2025

Upscaling production of immunogenic poliovirus virus-like particles in Pichia Pastoris by controlled fermentation

Lee Sherry, Keith Grehan, Mohammad W. Bahar…·Nicola J. Stonehouse

This study produces immunogenic poliovirus virus-like particles (VLPs) in Pichia pastoris through controlled fermentation, showing improved immunogenicity compared to current IPV vaccines.

5 citations

protein structureexperimental assay

𝕏 PostBluesky

MicrobiologyNature CommunicationsPeer-reviewedJan 18, 2025

Risk-free polio vaccine: Recombinant expression systems for production of stabilised virus-like particles

Lee Sherry, Mohammad W. Bahar, Claudine Porta…·David J. Rowlands

This study produces stabilized poliovirus VLPs using recombinant systems, showing equivalent or better immunogenicity than current vaccines.

23 citationstop 1%

humanprotein structure

𝕏 PostBluesky

GeneticsbioRxivPreprintJul 14, 2022

Genome-first detection of emerging resistance to novel therapeutic agents for SARS-CoV-2

Manon Ragonnet‐Cronin, Rungtiwa Nutalai, Jiandong Huo…·Sakib Rokadiya

The paper identifies mutations in SARS-CoV-2 variants that confer resistance to monoclonal antibodies by analyzing genomic data and validating their impact on antibody neutralization.

5 citations

humanwhole-genome sequencing

𝕏 PostBluesky